GLP-1 receptor agonists dominate the current conversation around metabolic research peptides. Three other compounds get far less attention.
MOTS-c, 5-Amino-1MQ, and AOD-9604 work through entirely different mechanisms. None of them touch the GLP-1 receptor at all.
This guide explains what MOTS-c, 5-Amino-1MQ, and AOD-9604 actually are. It also compares how their research mechanisms differ.
See Certified Peptide Solutions’ MOTS-c, 5-Amino-1MQ, and AOD-9604 research compounds.
What Is MOTS-c and How Does It Relate to Metabolic Research?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Unlike most peptides discussed in metabolic research, its genetic sequence comes from mitochondrial rather than nuclear DNA.
The foundational MOTS-c study identified skeletal muscle as a major experimental target and linked MOTS-c to cellular energy regulation through AMPK.
The mechanism is more specific than simply saying MOTS-c “activates AMPK.” In cell models, MOTS-c altered folate and purine metabolism, causing the intermediate AICAR to accumulate.
AICAR is an established AMPK activator, providing one proposed route between MOTS-c and downstream energy-sensing pathways.
Research has since expanded beyond that pathway.
A 2018 study of MOTS-c and mitonuclear signaling found that metabolic stress can drive MOTS-c into the nucleus, where it influences gene expression through AMPK-dependent and NRF2-related stress-response pathways.
More recently, a 2024 study identified CK2 as a direct MOTS-c-binding protein and found that suppressing CK2 weakened several measured skeletal-muscle responses in mice.
MOTS-c is therefore studied less as a single-pathway “AMPK peptide” and more as a mitochondrial signaling molecule involved in cellular stress and muscle metabolism.
A 2026 skeletal-muscle study further reported AMPK- and PGC-1α-dependent effects on mitochondrial bioenergetics, alongside lower mitochondrial ROS emission.
That expanding mechanistic literature is what makes MOTS-c distinct from receptor-based metabolic compounds such as GLP-1 agonists.
What Is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and cellular methyl-group metabolism. Despite often being sold alongside research peptides, 5-Amino-1MQ is not a peptide.
NNMT transfers a methyl group from SAM to nicotinamide, producing 1-methylnicotinamide (1-MNA). Because nicotinamide also feeds into NAD+ metabolism and SAM is a major cellular methyl donor, inhibiting NNMT can affect several connected metabolic pathways.
Importantly, 5-Amino-1MQ has compound-specific evidence rather than relying only on general NNMT research.
A 2017 study of small-molecule NNMT inhibitors found that 5-amino-1MQ-related methylquinolinium inhibitors were membrane-permeable and selective against the related methyltransferases and NAD+ salvage enzymes tested.
In adipocytes, NNMT inhibition reduced 1-MNA while increasing intracellular NAD+ and SAM. That connection places 5-Amino-1MQ within the broader nicotinamide and cofactor-metabolism research covered in our NAD+ mechanism overview.
Research has also moved beyond cell models. A 2024 mouse study characterized 5A1MQ pharmacokinetics and found distribution into metabolically active tissues including adipose tissue, skeletal muscle, and liver.
The study adds useful compound-specific exposure data, although several authors disclosed financial or employment ties to the compound’s developer. Overall, 5-Amino-1MQ is best understood as a research tool for studying NNMT inhibition, not as a stand-in for everything known about NNMT biology.
What Is AOD-9604 and What Research Question Does It Address?
AOD-9604 is a 16-amino-acid synthetic peptide based on the C-terminal region of human growth hormone. More precisely, it contains hGH residues 177–191 with an additional N-terminal tyrosine, rather than being a literal hGH(176–191) fragment.
The compound was developed to test whether metabolic activity associated with the C-terminal region of hGH could be studied separately from classical growth-hormone-receptor signaling.
In preclinical research, AOD-9604 did not compete for the human growth hormone receptor and did not reproduce the same proliferative response as intact hGH in the models tested. Animal studies also reported effects involving fat oxidation, lipolysis, and β3-adrenergic signaling, although the peptide’s direct molecular target remains unresolved.
AOD-9604 later progressed into human drug development, but the clinical evidence was not successful. A large Phase 2B obesity trial failed to show a statistically significant weight-loss benefit over placebo at its primary endpoint, and development for that indication was discontinued.
FDA’s later review likewise concluded that the available evidence did not establish AOD-9604 as an effective obesity treatment.
That history makes AOD-9604 most useful as a research compound for studying C-terminal GH-fragment biology, not as evidence of a proven clinical outcome.
How Do These Three Mechanisms Differ From GLP-1 Receptor Agonism?
None of these three compounds act on the GLP-1 receptor. Each one works through its own separate metabolic mechanism, shown below.
| Compound | Mechanism Category | Distinct From GLP-1? |
| MOTS-c | Mitochondrial-derived peptide, AMPK and mitonuclear signaling | Yes, no GLP-1 receptor involvement |
| 5-Amino-1MQ | NNMT enzyme inhibition (small molecule) | Yes, no GLP-1 receptor involvement |
| AOD-9604 | hGH-derived fragment, unresolved molecular target | Yes, no GLP-1 receptor involvement |
GLP-1 receptor agonists work through gut-hormone receptor signaling. That’s a completely different system from mitochondrial AMPK and mitonuclear signaling, NNMT enzyme inhibition, or an hGH-fragment pathway whose own target is still unknown.
For the GLP-1 side of this research area specifically, see Certified Peptide Solutions’ GLP-1 receptor agonist research overview.
Which Compound Matches Which Research Question?
Which compound fits depends entirely on the research question. Here’s how the three line up.
| Research Question | MOTS-c | 5-Amino-1MQ | AOD-9604 |
| Mitochondrial-derived peptide biology | Primary research fit | No | No |
| AMPK signaling | Major research pathway | Separate metabolic effects | Not established as primary mechanism |
| PGC-1α / mitochondrial bioenergetics | Direct current research | Not primary | No |
| CK2 signaling | Direct binding reported | No | No |
| NNMT inhibition | No | Direct molecular target | No |
| NAD+/SAM metabolic research | Indirect | Directly relevant to NNMT inhibition | No |
| Adipocyte NNMT studies | No | Strong fit | No |
| GH-fragment biology | No | No | Primary research rationale |
| Classical GH receptor binding | No | No | Not detected in key preclinical study |
| Beta-3 adrenergic / lipolysis models | No | No | Studied preclinically |
| Compound type | Peptide | Small molecule | Peptide |
These compounds aren’t substitutes for one another. MOTS-c is increasingly studied for mitochondrial signaling, involving AMPK, PGC-1α, and CK2. 5-Amino-1MQ is a compound-specific small-molecule tool for studying NNMT, with its own published target data. AOD-9604 is used to study GH-fragment biology, separate from the classical growth-hormone receptor pathway. Mechanism, research endpoint, and exact compound identity matter more here than the broad label “metabolic research compound.”
For how peptide research in this space compares more broadly, see the fat-loss peptide comparison overview.
Choosing a Compound for Metabolic Research
MOTS-c, 5-Amino-1MQ, and AOD-9604 often sit side by side in research catalogs. That doesn’t mean they answer the same question. The right compound for a given project depends on the receptor, enzyme, or pathway the research is actually built around, not which name sounds most familiar.
Sourcing MOTS-c, 5-Amino-1MQ, and AOD-9604 for Research
Identity confirmation matters for all three compounds, but for different reasons. MOTS-c and AOD-9604 are peptides. The same sequence-specific identity testing that applies to any research peptide applies here too.
5-Amino-1MQ is a small molecule. Its identity and purity testing uses small-molecule analytical methods instead of peptide-specific ones. That’s an important distinction. Don’t assume one testing framework covers all three compounds the same way.
The underlying principle is the same across any research compound. Get a batch-specific certificate of analysis. Make sure testing matches the actual material, peptide or small molecule. Confirm documentation is tied to the exact lot in hand.
Certified Peptide Solutions’ guide to reading a peptide certificate of analysis covers the peptide side of that process in more depth.
Frequently Asked Questions
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide, 16 amino acids long, encoded within the mitochondrial 12S rRNA gene. Researchers study MOTS-c for its connection to AMPK-dependent metabolic signaling and its effects on nuclear gene expression under metabolic stress.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule inhibitor of NNMT, an enzyme studied for its role in cellular energy metabolism. 5-Amino-1MQ is not a peptide, even though it’s sold and researched alongside peptide compounds.
What is AOD-9604?
AOD-9604 is a 16-amino-acid synthetic peptide built from the C-terminal region of human growth hormone. Researchers study AOD-9604 for its connection to lipolysis-related pathways, though AOD-9604’s exact molecular target remains unresolved.
How do MOTS-c, 5-Amino-1MQ, and AOD-9604 differ from GLP-1 receptor agonists?
None of these three compounds, MOTS-c, 5-Amino-1MQ, or AOD-9604, act on the GLP-1 receptor. MOTS-c is studied through mitochondrial and AMPK signaling, 5-Amino-1MQ through NNMT enzyme inhibition, and AOD-9604 through hGH-fragment biology, three separate mechanisms unrelated to GLP-1.
Did AOD-9604 succeed in human clinical trials?
No, AOD-9604 did not succeed in its major human clinical trial. A large Phase 2B obesity trial found no statistically significant weight-loss benefit for AOD-9604 over placebo, and development of AOD-9604 for that use was discontinued. AOD-9604 carries no FDA approval.
For laboratory research only. Not for human or veterinary use. Not for human consumption. No therapeutic, diagnostic, dosing, or treatment claims are made. See Certified Peptide Solutions’ Research Purposes Only policy for full research-use guidance.